dostęp otwarty

Tom 2, Nr 4 (2017)
Artykuły oryginalne / Original articles
Opublikowany online: 2017-01-19
Pobierz cytowanie

Time trends in tobacco-attributable cancer mortality in Poland — direct estimation method

Marta Mańczuk1, Urszula Sulkowska, Jakub Łobaszewski, Paweł Koczkodaj, Irena Przepiórka, Magdalena Cedzyńska, Krzysztof Przewoźniak, Joanna Didkowska
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2017;2(4):297-305.
Afiliacje
  1. Department of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Polska

dostęp otwarty

Tom 2, Nr 4 (2017)
Artykuły oryginalne / Original articles
Opublikowany online: 2017-01-19

Streszczenie

<strong>Introduction. </strong>Since the 20th century tobacco smoking has had an enormous impact on morbidity and mortality in the adult population, and it remains the greatest single preventable health risk factor worldwide. Cancer is the se­cond leading cause of death in Poland, with lung cancer as the primary cause of cancer-related death in Polish men and women. Given these statistics, this manuscript aims to estimate tobacco-attributable cancer mortality in Poland.
<strong>Material and methods. </strong>Data on cancer mortality come from the WHO Mortality Statistics database. Data on smoking prevalence in Poland come from standardized surveys based on nationally representative samples. Data on relative risks come from the Cancer Prevention Study II. Tobacco-attributable fractions were calculated using standard me­thodology for calculating population-based attributable fractions.
<strong>Results. </strong>In 2014, there were over 24 thousand tobacco-attributed cancer deaths in men. Lung cancer tops the list of ranked cancer types, with a tobacco-attributable fraction of 93%. Next is laryngeal (TAF = 90%), oropharyngeal (TAF = 86%) and esophageal (TAF = 80%) cancer. Overall, two-thirds of the considered cancer deaths were attributed to tobacco smoke (TAF = 75%). In 2014, there were over 7.5 thousand of cancer deaths related to smoking in women. Here, both laryngeal and lung cancer (both TAF = 76%) top the ranked list. Next are esophageal (TAF = 61%) and oropharyngeal (TAF = 51%) cancers, and when combined almost half of all considered cancer deaths were attributed to tobacco smoke (TAF = 44%).
<strong>Conclusions.</strong> Tobacco smoking and tobacco-attributable cancer mortality remain one of the greatest health burdens in Poles. Each year over 30 thousand Polish men and women die of cancer caused by smoking. All these deaths could be avoided.

Streszczenie

<strong>Introduction. </strong>Since the 20th century tobacco smoking has had an enormous impact on morbidity and mortality in the adult population, and it remains the greatest single preventable health risk factor worldwide. Cancer is the se­cond leading cause of death in Poland, with lung cancer as the primary cause of cancer-related death in Polish men and women. Given these statistics, this manuscript aims to estimate tobacco-attributable cancer mortality in Poland.
<strong>Material and methods. </strong>Data on cancer mortality come from the WHO Mortality Statistics database. Data on smoking prevalence in Poland come from standardized surveys based on nationally representative samples. Data on relative risks come from the Cancer Prevention Study II. Tobacco-attributable fractions were calculated using standard me­thodology for calculating population-based attributable fractions.
<strong>Results. </strong>In 2014, there were over 24 thousand tobacco-attributed cancer deaths in men. Lung cancer tops the list of ranked cancer types, with a tobacco-attributable fraction of 93%. Next is laryngeal (TAF = 90%), oropharyngeal (TAF = 86%) and esophageal (TAF = 80%) cancer. Overall, two-thirds of the considered cancer deaths were attributed to tobacco smoke (TAF = 75%). In 2014, there were over 7.5 thousand of cancer deaths related to smoking in women. Here, both laryngeal and lung cancer (both TAF = 76%) top the ranked list. Next are esophageal (TAF = 61%) and oropharyngeal (TAF = 51%) cancers, and when combined almost half of all considered cancer deaths were attributed to tobacco smoke (TAF = 44%).
<strong>Conclusions.</strong> Tobacco smoking and tobacco-attributable cancer mortality remain one of the greatest health burdens in Poles. Each year over 30 thousand Polish men and women die of cancer caused by smoking. All these deaths could be avoided.

Pobierz cytowanie

Słowa kluczowe

tobacco-attributable fraction, cancer, time trends, direct estimation method, tobacco-related cancer, cancer mortality, TAF, PAF

Informacje o artykule
Tytuł

Time trends in tobacco-attributable cancer mortality in Poland — direct estimation method

Czasopismo

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory

Numer

Tom 2, Nr 4 (2017)

Strony

297-305

Opublikowany online

2017-01-19

Wyświetlenia strony

372

Wyświetlenia/pobrania artykułu

486

Rekord bibliograficzny

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2017;2(4):297-305.

Słowa kluczowe

tobacco-attributable fraction
cancer
time trends
direct estimation method
tobacco-related cancer
cancer mortality
TAF
PAF

Autorzy

Marta Mańczuk
Urszula Sulkowska
Jakub Łobaszewski
Paweł Koczkodaj
Irena Przepiórka
Magdalena Cedzyńska
Krzysztof Przewoźniak
Joanna Didkowska

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, e-mail: viamedica@viamedica.pl